反向混合疗法与铋剂四联疗法根除幽门螺杆菌感染的随机对照试验显示等效
意向治疗分析显示两组根除率分别为96.6%和96.0%,差异无统计学意义(95%CI 8.0%~2.2%;P=.281)。反向混合疗法不良反应发生率(18.7%)低于铋剂四联疗法(47.7%)(P<.001)。
要点
- 14天反向混合疗法作为幽门螺杆菌一线治疗不劣于铋剂四联疗法。
- 意向治疗分析根除率:反向混合疗法组96.6% vs 铋剂四联疗法组96.0%,差异无统计学意义(P=.281)。
- 反向混合疗法不良反应发生率18.7%,低于铋剂四联疗法的47.7%(P<.001)。
核心结论
- 14天反向混合疗法作为幽门螺杆菌感染一线治疗不劣于铋剂四联疗法,且不良反应更少。
研究设计与样本
- 前瞻性随机对照试验,纳入幽门螺杆菌感染患者,随机分配至反向混合疗法组(n=176)或铋剂四联疗法组(n=176)。
- 研究于2015年8月至2017年2月进行。
- 反向混合疗法方案:质子泵抑制剂联合阿莫西林14天,克拉霉素联合甲硝唑前7天。
- 铋剂四联疗法方案:泮托拉唑、铋剂、四环素和甲硝唑14天。
- 主要结局为幽门螺杆菌感染治愈,依据尿素呼气试验阴性或组织学分析、尿素酶试验及细菌培养均阴性判定。
主要发现
- 意向治疗分析根除率:反向混合疗法组96.6% vs 铋剂四联疗法组96.0%,差异无统计学意义(95%CI 8.0%~2.2%;P=.281)。
- 克拉霉素耐药菌株根除率:反向混合疗法组88.2% vs 铋剂四联疗法组92.3%,无显著差异。
- 甲硝唑耐药菌株根除率:反向混合疗法组100% vs 铋剂四联疗法组96.9%,无显著差异。
- 不良反应发生率:反向混合疗法组18.7% vs 铋剂四联疗法组47.7%(P<.001)。
关键数值与推荐
- 美国推荐铋剂四联疗法作为幽门螺杆菌感染一线治疗,混合疗法为替代选择。
- 反向混合疗法为简化混合疗法:质子泵抑制剂联合阿莫西林14天,克拉霉素联合甲硝唑前7天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Bismuth quadruple therapy is recommended as a first-line treatment for Helicobacter pylori infection in the United States but hybrid therapy is an alternative option. Reverse hybrid therapy (proton pump inhibitor plus amoxicillin for 14 days, and clarithromycin plus metronidazole for the initial 7 days) is a simplified hybrid treatment. We aimed to assess the efficacies of reverse hybrid therapy vs bismuth quadruple therapy as first-line treatments for patients with H pylori infection in a randomized trial. METHODS: In a prospective study, patients with H pylori infection were randomly assigned to groups that received either reverse hybrid therapy (n = 176) or a bismuth quadruple therapy (pantoprazole, bismuth, tetracycline, and metronidazole for 14 days; n = 176). Patients were examined the end of therapy for adverse events. The study was performed from August 2015 through February 2017. The primary outcome was cure of H pylori infection, determined based on a negative result from the urea breath test, or negative results from histologic analysis, the urease test, and bacterial culture analyses. RESULTS: H pylori infection was eradicated from 96.6% of patients who received reverse hybrid therapy and 96.0% who received bismuth quadruple therapy-this difference was not significant in the intention-to-treat analysis (95% CI, 8.0% ∼ 2.2%; P = .281). There were no significant differences between therapies eradication of clarithromycin-resistant strains (88.2% with reverse hybrid therapy vs 92.3% with bismuth quadruple therapy) or metronidazole-resistant strains (100% vs 96.9%). However, reverse hybrid therapy was associated with fewer adverse events (18.7% of patients) than bismuth quadruple therapy (47.7%) (P < .001). CONCLUSIONS: In a randomized trial, we found 14-day reverse hybrid therapy to not be inferior to bismuth quadruple therapy as a first-line treatment for H pylori infection. Reverse hybrid therapy was associated with fewer adverse events. ClincialTrials.gov no: NCT02547038.
引用
- Hsu PI, Tsay FW, Graham DY, et al. Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of Helicobacter pylori Infection in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2018. PMID: 29609070. doi:10.1016/j.cgh.2018.03.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。